| Ticker | CRBU |
|---|---|
| ISIN | US1420381089 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment ...
El precio actual de Caribou Biosciences, Inc. (CRBU) es de 2,13 , con una variación del -5,75%.
Caribou Biosciences, Inc. opera en el sector Healthcare, industria Biotechnology.